COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targe ...

Novo Nordisk has agreed a partnership worth up to $2.2bn with US biotech Septerna, as the Danish drugmaker tries to shore up its pipeline of potential next-generation obesity drugs.

Novo Nordisk A/S is partnering with U.S. biotech Septerna Inc. on the development of oral pills for obesity in a deal potentially worth up to $2.2 billion. The two companies will start with four ...

Novo Nordisk stock DK:NOVO.B NVO rose 2% in Copenhagen trade. But the stock is still down about 28% this year and less than half the value of its peak last June. Partner Center.

Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to stem sales of copies of ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company currently is the leading player.

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

Novo Nordisk said it's paying $200 million upfront and up to $1.8 billion in milestone payments to United Laboratories International for the right to license a drug, outside of China that is in ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company The United Bio-Technology Co., as it looks to boost ...